|Title||One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus|
|Author(s)||Asseldonk, E.J.P. van; Poppel, P.C.M. van; Ballak, D.B.; Stienstra, Rinke; Netea, M.G.; Tack, C.J.|
|Source||Clinical Immunology 160 (2015)2. - ISSN 1521-6616 - p. 155 - 162.|
Chair Nutrition Metabolism and Genomics
|Publication type||Refereed Article in a scientific journal|
|Keyword(s)||Adipose tissue - Anakinra - Inflammation - Insulin sensitivity - Interleukin 1 - Type 1 diabetes|
Inflammation associated with obesity is involved in the development of insulin resistance. We hypothesized that anti-inflammatory treatment with the Interleukin-1 receptor antagonist anakinra would improve insulin sensitivity.In an open label proof-of-concept study, we included overweight patients diagnosed with type 1 diabetes with an HbA1c level over 7.5%. Selecting insulin resistant patients with longstanding type 1 diabetes allowed us to study the effects of anakinra on insulin sensitivity. Patients were treated with 100. mg anakinra daily for one week. Insulin sensitivity, insulin need and blood glucose profiles were measured before, after one week and after four weeks of follow-up.Fourteen patients completed the study. One week of anakinra treatment led to an improvement of insulin sensitivity, an effect that was sustained for four weeks. Similarly, glucose profiles, HbA1c levels and insulin needs improved.In conclusion, one week of treatment with anakinra improves insulin sensitivity in patients with type 1 diabetes.